Please Note: Due to volume considerations, not all questions can be answered. Questions most likely to be answered will be those of general interest to a broad group of visitors to this forum. Questions pertaining to a specific case; requests for diagnosis, medical advice, or second opinion; or requests for opinions about untested alternative therapies will generally not be answered.
The participation of Dr. Joseph McGowan in this
Forum is made possible by Boehringer Ingelheim.
|
|
 |
|
Fuzeon with SSR5 Trial Study Meds
Jun 14, 2006
Hi Carol,
After 20 years of HIV+ treatment, I became resistive to ALL HAART medication combinations in 2005. I then began Fuzeon (injectable) treatment, December 2005. In order for the Fuzeon to work effectively, I also began SSR5 Trial Study medication to provide necessary active supplemental medication. SR4 count rose from 67 to 587, SR4% from 7% to 16%, and Viral Load decreaseed from 587,000 to Undetectable.
This may be a solution for a paitient on Fuzeon, but the supplement backups are failing and becoming inactive, and therefore it appears that the Fuzeon treatment is failing as well. SSR5 provides a new class of treatment not included in HAART.
Your comments to me would be appreciated.
Alan in San Antonio
|
 |
|
 |
|
Response from Ms. Salisbury
Hi Alan,
I am aware of the new Entry Inhibitors that you speak of. They are specific to the receptor sites on the T cell. They prevent the HIV from attaching to the T-cell. Therefore, the virus is unable to infect the T cell. There are a couple new ones on the market. The one I know that is in expanded access is made by Pfizer and is called Maraviroc. The others are a little behind in marketing. They are aplaviroc and vicriviroc. They are showing very good response in patients that have the specific receptor site that is named CCR5. There are usually two receptor sites on the T-cell -- CCR5 and CXCR4. Genetics (what you get at birth) predict our receptor sites on the T cell. Unfortunately, some people have only the CXCR4 receptor sites therefore the new Entry Inhibitors will not stop the virus from infecting the T-cell.
We have learned a lot about the HIV virus and now can explain why some people never get the HIV infection and some get a less infectious form. It all has to do with the receptor sites on the T cell.
I am pleased you are responding to this new class of HIV treatment. Good luck and know there are many new drugs coming in the next few years. There will be a new protease inhibitor soon.
Carol
|
|
|
 Please remember that this forum is designed for educational purposes only, and experts are not engaged through this
forum in rendering legal or medical advice or professional services. Experts appearing on this page are independent and are solely responsible
for editing and fact-checking their material. Neither The Body nor any sponsor is the publisher or speaker of posted visitors' questions or the experts' material.
Questions and messages posted to this forum are not statements of advice, opinion, or information of The Body, Body Health Resources Corporation or any sponsor of this
forum. While neither The Body nor Body Health Resources Corporation regularly reviews posted content, we reserve the right to delete, move, or
edit postings if we deem it appropriate under the circumstances. Visitors submitting questions remain solely responsible for the content of their
messages.
Information provided by experts is general only and should not be used for diagnosing or treating a health problem or a disease, or relied upon as
legal or other professional advice. This information is not a substitute for professional advice or care. If you have or suspect you may have a
health or legal problem, you should consult your own health care provider or your attorney.
Copyright notice.
|
|
|
|
